Archive for September 20th, 2008

Drug Cost Management Report - Johnson & Johnson officials discussed new indications for Topamax - Brief Article

Saturday, September 20th, 2008

* Johnson & Johnson officials discussed new indications for Topamax (topiramate), during a conference call on the company’s second quarter 2003 earnings. Topamax is a widely prescribed drug with indications for seizure disorders and bipolar disorder. With its recent launch of Axert for migraine headaches, the company is entering the migraine market, but its bigger plans are for Topamax as a preventive therapy for migraines.